PriceTargets.com logo

Nabriva Therapeutics - NBRV Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $50.00
  • Forecasted Upside: 2,790.17%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.73 As of 03/22/2023 03:33 PM ET
▲ +0.02 (1.17%)

This chart shows the closing price for NBRV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nabriva Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NBRV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NBRV

Analyst Price Target is $50.00
▲ +2,790.17% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Nabriva Therapeutics in the last 3 months. The average price target is $50.00, with a high forecast of $50.00 and a low forecast of $50.00. The average price target represents a 2,790.17% upside from the last price of $1.73.

This chart shows the closing price for NBRV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Sell

The current consensus among 1 investment analysts is to sell stock in Nabriva Therapeutics. This rating has held steady since May 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/25/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/23/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/22/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/22/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/6/2023Northland SecuritiesDowngradeOutperform ➝ UnderperformLow
3/30/2022Northland SecuritiesLower TargetOutperform$100.00 ➝ $50.00High
5/26/2021HC WainwrightReiterated RatingNeutralLow
3/12/2021Northland SecuritiesLower TargetOutperform$225.00 ➝ $150.00Medium
9/11/2020HC WainwrightReiterated RatingHoldHigh
8/7/2020HC WainwrightReiterated RatingHoldHigh
6/22/2020Northland SecuritiesLower TargetOutperform$62.50 ➝ $37.50High
6/22/2020HC WainwrightReiterated RatingHoldHigh
4/23/2020Northland SecuritiesLower TargetOutperform$125.00 ➝ $62.50Low
4/19/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
4/9/2020HC WainwrightDowngradeBuy ➝ Neutral$175.00High
4/8/2020Needham & Company LLCDowngradeBuy ➝ HoldLow
3/19/2020WedbushDowngradeOutperform ➝ Neutral$150.00 ➝ $25.00High
3/17/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$175.00 ➝ $50.00Medium
3/13/2020Needham & Company LLCLower TargetBuy$250.00 ➝ $125.00High
3/13/2020HC WainwrightReiterated RatingBuy$175.00High
11/15/2019WedbushReiterated RatingOutperform$175.00High
11/13/2019Needham & Company LLCReiterated RatingBuyHigh
8/20/2019Bank of AmericaSet TargetBuy$150.00Medium
8/18/2019HC WainwrightSet TargetBuy$175.00High
8/16/2019Northland SecuritiesSet TargetBuy$325.00High
8/9/2019WedbushReiterated RatingOutperform$125.00High
8/8/2019Northland SecuritiesReiterated RatingBuy$312.50High
5/9/2019HC WainwrightReiterated RatingBuy$175.00Medium
5/8/2019Northland SecuritiesSet TargetBuy$325.00Medium
5/2/2019GabelliUpgradeSell ➝ Hold$50.00Low
5/2/2019HC WainwrightReiterated RatingBuy ➝ Buy$225.00 ➝ $175.00Medium
5/1/2019Needham & Company LLCReiterated RatingBuy$375.00 ➝ $250.00High
3/27/2019GabelliDowngradeBuy ➝ Sell$64.00High
3/13/2019HC WainwrightReiterated RatingBuy$225.00High
3/12/2019Northland SecuritiesReiterated RatingBuy$312.50Low
1/28/2019HC WainwrightReiterated RatingBuy$225.00Low
11/14/2018SunTrust BanksLower TargetBuy$275.00High
9/7/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$200.00High
8/27/2018Bank of AmericaSet TargetBuy ➝ Buy$225.00 ➝ $125.00Medium
8/9/2018Needham & Company LLCSet TargetBuy$450.00High
7/25/2018Needham & Company LLCReiterated RatingBuy$450.00High
5/31/2018Northland SecuritiesInitiated CoverageOutperformMedium
5/30/2018Cantor FitzgeraldSet TargetBuy$400.00Low
5/22/2018Bank of AmericaBoost TargetBuy ➝ Buy$250.00 ➝ $275.00High
5/21/2018Cantor FitzgeraldSet TargetBuy$400.00High
5/8/2018Needham & Company LLCReiterated RatingBuy$450.00Medium
5/8/2018Cantor FitzgeraldSet TargetBuy$400.00Medium
(Data available from 3/22/2018 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/24/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2022
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/22/2023

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Nabriva Therapeutics logo
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $1.73
Low: $1.69
High: $1.79

50 Day Range

MA: $1.66
Low: $1.41
High: $1.90

52 Week Range

Now: $1.73
Low: $1.22
High: $12.80

Volume

32,468 shs

Average Volume

43,776 shs

Market Capitalization

$53.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Nabriva Therapeutics?

The following Wall Street sell-side analysts have issued reports on Nabriva Therapeutics in the last year: Northland Securities, and StockNews.com.
View the latest analyst ratings for NBRV.

What is the current price target for Nabriva Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Nabriva Therapeutics in the last year. Their average twelve-month price target is $50.00, suggesting a possible upside of 2,693.5%. Northland Securities has the highest price target set, predicting NBRV will reach $50.00 in the next twelve months. Northland Securities has the lowest price target set, forecasting a price of $50.00 for Nabriva Therapeutics in the next year.
View the latest price targets for NBRV.

What is the current consensus analyst rating for Nabriva Therapeutics?

Nabriva Therapeutics currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe NBRV will underperform the market and that investors should sell shares of Nabriva Therapeutics.
View the latest ratings for NBRV.

What other companies compete with Nabriva Therapeutics?

Other companies that are similar to Nabriva Therapeutics include HCW Biologics, Galecto, DiaMedica Therapeutics, FSD Pharma and Lantern Pharma. Learn More about companies similar to Nabriva Therapeutics.

How do I contact Nabriva Therapeutics' investor relations team?

Nabriva Therapeutics' physical mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The biotechnology company's listed phone number is (531) 649-2000 and its investor relations email address is [email protected] The official website for Nabriva Therapeutics is www.nabriva.com. Learn More about contacing Nabriva Therapeutics investor relations.